University of College London Hospitals (UCLH) Selects GEO SCAN Medical as New Standard of Care for the Detection and Treatment of Prostate Cancer

Revolutionary 3D MR Fusion technology BioJet™ chosen for its ability to improve clinical information and enhance patient outcomes

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We've been seeking a solution to the challenge of how to reliably fuse two modalities for more precise biopsy - and this now provides that capability.

Sarasota, FL (PRWEB) December 04, 2012

University of College London Hospitals (UCLH) has selected GEO SCAN Medical as its new standard of care for the diagnosis, management and treatment of prostate cancer. The BioJet™ solution, a unique, cost-effective 3D MR Fusion technology, will dramatically change the way prostate cancer is treated and managed. The goal is to strengthen care delivery by reliably fusing MR images with real-time ultrasound, which greatly increases visibility of the “regions of interest” for prostate biopsy.

BioJet is a minimally invasive software/hardware platform which received final approval 510(k) clearance from the Food and Drug Administration (FDA) in August 2012, and the European CE Mark Approval in January.

“After completing three successful cases,” said Dr. Mark Emberton, M.D., UCL, "we found that the BioJet software enables more precise results. We will continue to test the limits of fusion technology as our new standard of prostate care." In 2012, the academic hospital enlisted GEO SCAN to provide better information for staging of prostate cancer, in order to determine the best clinical path and course treatment for optimal outcomes.

In addition to the success at UCLH, GEO SCAN has also recently launched its first MR Fusion cases in the United States. Michael S. McGuire, M.D., has been using the system as of October at NorthShore University HealthSystem. McGuire, Co-Director of the John and Carol Walter Center for Urological Health, said: "We've been seeking a solution to the challenge of how to reliably fuse two modalities for more precise biopsy - and this now provides that capability."

GEO SCAN's worldwide sales and distribution activities have already resulted in multiple success cases. GEO SCAN's goal is to expand the BioJet technology with its distribution partners into these territories: EMEA (Europe, Middle East and Africa), Asia and Pacific Rim; as well as the Americas (North and South).

"As the industry moves toward new care models, we're pleased to pave the way for innovative approaches in the detection, treatment and management of prostate cancer," said Manfred Sablowski, chief executive officer of GEO SCAN Medical. "With enhanced visibility, caregivers can now clearly define regions of interest for biopsy - which will ultimately allow better staging and improved clinical outcomes."

GEO SCAN Medical is a global medical device company that develops, manufactures and markets innovative products in the field of minimally invasive Ultrasound and MR image guided medical procedures. For more information, please visit http://www.geoscanmedical.com.


Contact